Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zymeworks (ZYME) Common Equity (2021 - 2025)

Zymeworks' Common Equity history spans 5 years, with the latest figure at $268.5 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 20.74% to $268.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $268.5 million, a 20.74% decrease, with the full-year FY2025 number at $268.5 million, down 20.74% from a year prior.
  • Common Equity hit $268.5 million in Q4 2025 for Zymeworks, down from $320.1 million in the prior quarter.
  • Over the last five years, Common Equity for ZYME hit a ceiling of $493.0 million in Q4 2022 and a floor of $179.8 million in Q3 2022.
  • Historically, Common Equity has averaged $350.8 million across 5 years, with a median of $336.6 million in 2024.
  • Biggest five-year swings in Common Equity: tumbled 35.55% in 2022 and later skyrocketed 136.06% in 2023.
  • Tracing ZYME's Common Equity over 5 years: stood at $249.1 million in 2021, then surged by 97.9% to $493.0 million in 2022, then fell by 5.71% to $464.8 million in 2023, then dropped by 27.12% to $338.8 million in 2024, then fell by 20.74% to $268.5 million in 2025.
  • Business Quant data shows Common Equity for ZYME at $268.5 million in Q4 2025, $320.1 million in Q3 2025, and $334.5 million in Q2 2025.